The development and characterization of a CRISPR/Cas9-mediated PD-1 functional knockout rat as a tool to study idiosyncratic drug reactions

• Published in: Toxicological sciences 2024-03, Vol.198 (2), p.233-245
• Main Authors: Cho, Tiffany, Wierk, Antonia, Gertsenstein, Marina, Rodgers, Christopher E, Uetrecht, Jack, Henderson, Jeffrey T
• Format: Article
• Language: English
• Subjects: Animals; CRISPR-Cas Systems; Drug-Related Side Effects and Adverse Reactions; Humans; Liver - metabolism; Mammals - metabolism; Mice; Models, Animal; Nevirapine - metabolism; Nevirapine - toxicity; Programmed Cell Death 1 Receptor - metabolism; Rats
• ISSN: 1096-6080; 1096-0929
• DOI: 10.1093/toxsci/kfae003

Idiosyncratic drug reactions are rare but serious adverse drug reactions unrelated to the known therapeutic properties of the drug and manifest in only a small percentage of the treated population. Animal models play an important role in advancing mechanistic studies examining idiosyncratic drug reactions. However, to be useful, they must possess similarities to those seen clinically. Although mice currently represent the dominant mammalian genetic model, rats are advantageous in many areas of pharmacologic study where their physiology can be examined in greater detail and is more akin to that seen in humans. In the area of immunology, this includes autoimmune responses and susceptibility to diabetes, in which rats more accurately mimic disease states in humans compared with mice. For example, oral nevirapine treatment can induce an immune-mediated skin rash in humans and rats, but not in mice due to the absence of the sulfotransferase required to form reactive metabolites of nevirapine within the skin. Using CRISPR-mediated gene editing, we developed a modified line of transgenic rats in which a segment of IgG-like ectodomain containing the core PD-1 interaction motif containing the native ligand and therapeutic antibody domain in exon 2 was deleted. Removal of this region critical for mediating PD-1/PD-L1 interactions resulted in animals with an increased immune response resulting in liver injury when treated with amodiaquine.